Explore

Trendline Trendline
Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Trendline Trendline
Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026

Alnylam Pharmaceuticals to Showcase Vutrisiran Data at Heart Failure 2026
Trendline Trendline
FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals
Trendline Trendline
Erasca Shares Plummet Amid Patient Death and Patent Dispute

Erasca Shares Plummet Amid Patient Death and Patent Dispute

Erasca Shares Plummet Amid Patient Death and Patent Dispute
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
Teva Acquires Emalex for $900 Million, Expanding Neurology Portfolio

Teva Acquires Emalex for $900 Million, Expanding Neurology Portfolio

Teva Acquires Emalex for $900 Million, Expanding Neurology Portfolio
Trendline Trendline
FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval

FDA Advisory Committee Recommends Against AstraZeneca's Breast Cancer Drug Approval